CRIS Current Research Information System

DI MARCO, MARIACRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.971
AS - Asia 8.469
EU - Europa 6.332
AF - Africa 648
SA - Sud America 461
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 24.901
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.840
VN - Vietnam 2.310
CN - Cina 2.205
SG - Singapore 2.142
IT - Italia 1.447
GB - Regno Unito 1.227
SE - Svezia 782
DE - Germania 724
HK - Hong Kong 570
FR - Francia 394
IN - India 374
BR - Brasile 323
RU - Federazione Russa 282
CH - Svizzera 277
IE - Irlanda 249
NL - Olanda 225
UA - Ucraina 211
KR - Corea 168
CI - Costa d'Avorio 153
BD - Bangladesh 146
FI - Finlandia 141
ZA - Sudafrica 140
TG - Togo 129
JP - Giappone 128
SC - Seychelles 87
EE - Estonia 86
NG - Nigeria 83
CA - Canada 72
AT - Austria 68
PH - Filippine 65
JO - Giordania 58
BG - Bulgaria 53
AR - Argentina 44
TH - Thailandia 42
ID - Indonesia 41
BE - Belgio 37
TR - Turchia 30
ES - Italia 28
IQ - Iraq 28
MX - Messico 27
EC - Ecuador 26
CL - Cile 24
PK - Pakistan 23
PL - Polonia 22
TW - Taiwan 22
IR - Iran 16
UZ - Uzbekistan 15
CO - Colombia 13
SA - Arabia Saudita 13
GR - Grecia 12
LB - Libano 12
HR - Croazia 11
LT - Lituania 11
MY - Malesia 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
DZ - Algeria 10
EG - Egitto 9
NP - Nepal 9
JM - Giamaica 8
PT - Portogallo 8
PY - Paraguay 8
VE - Venezuela 8
NI - Nicaragua 7
PE - Perù 7
CZ - Repubblica Ceca 6
PS - Palestinian Territory 6
CR - Costa Rica 5
HU - Ungheria 5
MA - Marocco 5
RO - Romania 5
TN - Tunisia 5
UY - Uruguay 5
AZ - Azerbaigian 4
ET - Etiopia 4
KE - Kenya 4
KZ - Kazakistan 4
RS - Serbia 4
SN - Senegal 4
BO - Bolivia 3
DK - Danimarca 3
EU - Europa 3
MU - Mauritius 3
OM - Oman 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AG - Antigua e Barbuda 2
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
CM - Camerun 2
CW - ???statistics.table.value.countryCode.CW??? 2
DO - Repubblica Dominicana 2
HN - Honduras 2
IL - Israele 2
ME - Montenegro 2
MM - Myanmar 2
MT - Malta 2
SK - Slovacchia (Repubblica Slovacca) 2
AO - Angola 1
Totale 24.874
Salva come PNG Salva come JPEG
Città #
Singapore 1.475
Southend 1.055
Ashburn 976
Chandler 694
Fairfield 683
Hong Kong 524
Ho Chi Minh City 511
Hanoi 457
San Jose 451
Santa Clara 338
Dallas 337
Houston 327
Hefei 317
Princeton 285
Beijing 277
Woodbridge 275
Bologna 267
Bern 266
Wilmington 261
Dong Ket 256
Dublin 249
Seattle 245
Ann Arbor 231
Boardman 213
Cambridge 211
New York 199
Los Angeles 187
Abidjan 153
Lauterbourg 152
Seoul 134
Lomé 129
Council Bluffs 128
Helsinki 118
Jacksonville 112
Nanjing 112
Westminster 109
Tokyo 101
Padova 98
Milan 95
Berlin 82
Da Nang 78
Turin 76
Haiphong 74
Rome 73
Jinan 71
Frankfurt am Main 70
Shenyang 67
Buffalo 66
Abeokuta 65
Medford 65
Florence 64
Shanghai 59
Redondo Beach 58
Amman 55
Tianjin 54
Sofia 53
Guangzhou 52
Redmond 51
São Paulo 47
Munich 46
San Diego 46
Saint Petersburg 45
Hebei 40
Changsha 38
Nanchang 37
Hangzhou 35
Johannesburg 34
Vienna 34
Brussels 32
Dearborn 32
Des Moines 32
Mülheim 30
Nuremberg 30
Bengaluru 29
Falkenstein 29
Falls Church 29
Brooklyn 27
Hải Dương 27
London 26
Tongling 26
Biên Hòa 25
Orem 25
Amsterdam 24
Bremen 24
Chicago 24
Zhengzhou 24
Atlanta 23
Jiaxing 23
Phoenix 23
Bến Tre 22
Can Tho 22
Jakarta 22
Toronto 22
Taiyuan 21
Redwood City 20
Yubileyny 20
Montreal 19
Bühl 18
San Francisco 18
Shenzhen 18
Totale 15.429
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 465
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 304
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 290
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 274
β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer 267
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 261
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: a single center prospective, randomized controlled study. 260
Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients 255
Adjuvant chemoradiation in pancreatic cancer: Impact of radiotherapy dose on survival 251
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 250
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 249
The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study 245
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 243
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 238
Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. 237
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 235
Comparing recist and Choi’s criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer 232
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 230
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 228
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre 225
Mutational burden of resectable pancreatic cancer by whole-transcriptome and whole-exome sequencing could predict a poor prognosis 225
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 223
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 222
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 221
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 219
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 219
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 216
Intraductal papillary mucinous neoplasms: the bologna experience. Lessons learned from 357 cases observed in a tertiary care center 214
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 213
Intraductal Papillary Mucinous Neoplasms: The Bologna Experience 207
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 204
Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression 203
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 203
Multicolour versus monocolour inking specimens after pancreaticoduodenectomy for periampullary cancer: A single centre prospective randomised clinical trial 202
Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1) 201
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 198
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 197
In Reply 195
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 195
Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 193
Branch duct intraductal papillary mucinous neoplasm: validation of Fukuoka 2012 guidelines using a systematic review and meta-analysis 191
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 191
Discovery of new potential actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 190
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 190
Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses 188
The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study 187
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study 186
GemOx and Ovarian Pancreatic Cancer Metastasis (PC) 186
Treatment of colorectal cancer liver metastases 184
Clinical impact of nonselective beta-blockers on survival in patients with pancreatic cancer- revival of well known drugs? 184
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 182
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 182
State of the art biological therapies in pancreatic cancer 181
Pancreatic ductal adenocarcinoma associated with autoimmune pancreatitis. 181
Comparing RECIST and Choi's Criteria After Neoadjuvant Chemoradiotherapy in Patients with Resectable Pancreatic Cancer 178
Prospective validation of a preoperative risk score model based on pancreatic texture to predict postoperative pancreatic fistula after pancreaticoduodenectomy. 178
Capecitabine(CAP) based regimens vs infusional 5FU/AF in metastatic colorectal cancer cost/effectivness: the differences across the atlantic ocean 175
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 174
Immunonutrition in patients who underwent major abdominal surgery: A comprehensive systematic review and component network metanalysis using GRADE and CINeMA approaches 174
Advanced pancreatic cancer (APC) A monocenter experience in 53 patients: is it possible a second line treatment? 173
Pancreatic cyst surveillance imposes low psychological burden 173
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib 173
Intraductal papillary mucinous neoplasms: the Bologna experience. Lessons learned from 357 cases observed in a tertiary care center 172
Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study 172
Risk Factors in Resected Pancreatic Cancer. A Single Centre Experience 171
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 171
Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets 170
External validation of nomogram for predicting malignant intraductal papillary mucinous neoplasm (IPMN): from the theory to the clinical practice using the decision curve analysis model 168
Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1) 167
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 166
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI) 164
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 164
Hacking pancreatic cancer: Present and future of personalized medicine 163
Erratum: β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer (Cancer Cell (2018) 33(1) (75–90.e7), (S153561081730510X) (10.1016/j.ccell.2017.11.007)) 160
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 159
Gemox in combination witherlotinib (E) in pancreatic cancer (PC). 159
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice—a fifteen-year journey at a tertiary referral centre 158
Advanced pancreatic cancer (apc); a Monocenter experience in 53 patients. It is possible a second line treatment? 158
Intervento educativo rivolto a giovani fumatori della scuola secondaria di secondo grado 157
Preoperatory Gemcitabine and Oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma 157
EXOCRINE-ENDOCRINE PANCREATIC CANCER AND alpha-FETOPROTEIN 157
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOINSTITUTIONAL EXPERIENCE 156
The follow-up issues: from the necessity to the opportunity 155
Risk Factors for Malignancy of Branch-Duct Intraductal Papillary Mucinous Neoplasms: A Critical Evaluation of the Fukuoka Guidelines With a Systematic Review and Meta-analysis 155
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 155
CIRCULATING METALLOPROTEINASE-3 AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 IN PATIENTS WITH DUCTAL PANCREATIC NEOPLASMS 154
Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results - a single‑center experience 154
Whole Transcriptome Sequencing Reveals Molecular Prognostic Markers in Pancreatic Adenocarcinoma 152
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? 151
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. 151
Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients. 150
Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1) 149
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma. 149
Prognostic factors for recurrence in resected pancreatic adenocarcinoma: a single center experience 148
Whole-transcriptome paired-end sequencing and the pancreatic cancer genetic landscape 148
Locally Advanced Pancreatic Cancer: Is There a Role for Neoadjuvant Chemo-Radiation? A Case Report and Literature Review 146
Hedgehog Signaling: from the Cuirass to the Heart of Pancreatic Cancer 146
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 146
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? 145
Massively Parallel Sequencing Analysis of Genetic Alterations Carried by Pancreatic Adenocarcinoma 145
Totale 19.378
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.658
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.658
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.699 194 106 96 201 228 125 66 179 151 264 651 438
2022/20233.334 302 476 178 370 227 254 51 192 499 127 305 353
2023/20241.039 88 130 84 95 81 270 50 62 25 69 52 33
2024/20253.438 172 429 275 240 474 167 273 192 53 333 173 657
2025/20269.348 716 731 870 624 873 466 1.340 323 1.903 752 417 333
2026/2027170 170 0 0 0 0 0 0 0 0 0 0 0
Totale 25.445